关于公司全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 根据全国高新技术企业认定管理工作领导小组于近日发布的《对重庆市认定机 构 2025 年认定报备的第三批高新技术企业进行备案的公告》，重庆华森制药股份 有限公司（以下简称"公司"）全资子公司重庆华森英诺生物科技有限公司（以下 简称"华森英诺"）被认定为 2025 年度第三批国家高新技术企业，证书编号为 GR202551102448，有效期三年。 证券代码：002907 证券简称：华森制药 公告编号：2026-002 重庆华森制药股份有限公司 特此公告 重庆华森制药股份有限公司 董事会 2026 年 1 月 14 日 本次系华森英诺首次被认定为高新技术企业。根据《中华人民共和国企业所得 税法》等有关规定，华森英诺自获得高新技术企业认定后的连续三年内，将享受高 新技术企业所得税优惠政策，即可按 15%的税率缴纳企业所得税。本次认定事项不 会对公司当期经营业绩产生影响，敬请广大投资者理性投资，注意防范投资风险。 ...

简式权益变动报告书 上市公司名称：重庆华森制药股份有限公司 股票上市地点：深圳证券交易所 股票简称：华森制药 重庆华森制药股份有限公司 股票代码：002907 信息披露义务人1：成都地方建筑机械化工程有限公司 住所及通讯地址：成都市郫都区友爱镇释迦桥下街166号22栋1楼166号 信息披露义务人2：游洪涛、王瑛 住所及通讯地址：重庆市渝北区**** 信息披露义务人3：上海添橙投资管理有限公司－添橙添利一号私募证券投资基金 住所及通讯地址：上海市静安区 股份变动：股份减少 签署日期：二〇二六年一月十三日 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》、《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以 下简称"《准则15号》"）及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 第一节 释义 | 信息披露义务人 | 指成都地方建筑机械化工程有限公司及其一致行动 | | --- | --- | | | 人游洪涛、王瑛、上海添橙投资管理 ...

证券代码：002907 证券简称：华森制药 公告编号：2026-001 重庆华森制药股份有限公司 关于控股股东及其一致行动人权益变动的提示性公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、王瑛 女士、上海添橙投资管理有限公司-添橙添利一号私募证券投资基金保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动前信息披露义务人合计持有公司股份 292,317,525 股，占公 司总股本的 70.00%。 2、2025 年 1 月 23 日至 2026 年 1 月 13 日期间，公司控股股东成都地建通 过集中竞价及大宗交易的方式减持公司股份 14,373,176 股，占公司总股本 3.44%； 游洪涛先生通过大宗交易方式减持公司股份 5,965,965 股，占公司总股本 1.43%； 添橙添利一号私募基金通过集中竞价方式减持公司股份 540,780 股，占公司总股 本 0.13%。信息披露义务人合计持有公司股份 271,437,604 股，合计持有公司股 1、本次权 ...

Core Viewpoint - The announcement from Huason Pharmaceutical indicates a planned reduction in shareholding by major shareholders, which will not affect the company's control or trigger a mandatory bid [1] Shareholding Changes - The controlling shareholders, Chengdu Dajian, You Hongtao, and Tian Cheng Tian Li No. 1 Private Fund, collectively held 292 million shares, accounting for 70% of the total share capital before the reduction [1] - Chengdu Dajian reduced its holdings by 14.3732 million shares (3.44%), You Hongtao by 5.966 million shares (1.43%), and Tian Cheng Tian Li No. 1 Private Fund by 540,800 shares (0.13%) [1] - After the reduction, the total shareholding of these three parties decreased to 271 million shares, representing 65% of the total share capital [1]

Summary of Key Points Core Viewpoint - Huason Pharmaceutical's stock rose by 3.38% to close at 15.91 yuan, with significant block trades occurring on January 13, indicating potential investor interest and market activity [1]. Trading Activity - Two major block trades were recorded, totaling 1,200,700 shares and a transaction value of 16.81 million yuan [1]. - The first trade involved 170,000 shares at a price of 14.00 yuan, with a transaction value of 2.38 million yuan and a discount rate of -12.01% [1]. - The second trade involved 1,030,700 shares at the same price of 14.00 yuan, with a transaction value of 14.43 million yuan and the same discount rate of -12.01% [1]. Recent Performance - Over the past three months, Huason Pharmaceutical has seen a total of 21 block trades, accumulating a transaction value of 84.59 million yuan [1]. - In the last five trading days, the stock has increased by 4.67%, with a net inflow of 6.71 million yuan from major funds [1].

Group 1 - The core point of the article is that Huason Pharmaceutical executed a block trade of 1.2007 million shares, amounting to 16.8096 million yuan, which represents 8.14% of the total trading volume for the day [1] - The transaction price was 14 yuan per share, reflecting a discount of 12.01% compared to the market closing price of 15.91 yuan [1]

Group 1 - On January 8, Huason Pharmaceutical executed a block trade of 152,800 shares, with a transaction value of 2.101 million yuan, accounting for 4.59% of the total transaction volume for the day [1] - The transaction price was 13.75 yuan, which represents a discount of 10.25% compared to the market closing price of 15.32 yuan [1]

Group 1 - On January 7, Huason Pharmaceutical executed a block trade of 165,000 shares, with a transaction value of 2.2572 million yuan, accounting for 4.71% of the total trading volume for the day [1][2] - The transaction price was 13.68 yuan, representing a discount of 10.47% compared to the market closing price of 15.28 yuan [1][2]

进一步统计，近3个月内该股累计发生17笔大宗交易，合计成交金额为6342.64万元。该股近5个交易日 累计下跌0.20%，主力资金合计净流出1101.66万元。 责任编辑：小浪快报 第1笔成交价格为13.66元，成交14.65万股，成交金额200.12万元，溢价率为-10.13%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司宜都长江大道证券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月6日，华森制药收涨0.13%，收盘价为15.20元，发生1笔大宗交易，合计成交量14.65万股，成交金额 200.12万元。 ...

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval for a change in its production license for special medical purpose formula foods, expanding its product range [1][4]. Group 1: License Change - The company has obtained a new production license for special medical purpose formula foods, which includes an expanded range of food categories [1]. - The updated license is issued by the Chongqing Municipal Market Supervision Administration [1]. Group 2: Product Information - The company's Gan Yimei liquid formula food is designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber [2]. - The product provides a high carbohydrate energy ratio of 87%, ensuring quick energy supply with minimal digestive burden, and includes essential vitamins and minerals for balanced nutrition [2]. - It is suitable for nutritional support in conditions such as acute pancreatitis and short bowel syndrome, and can also be used as a standardized liquid diet before colonoscopy [2]. Group 3: Market Potential - The global market for special medical purpose formula foods is estimated to reach $24.8 billion in 2024, with a projected compound annual growth rate (CAGR) of 5.13%, reaching $33.49 billion by 2030 [2]. - In China, the market size for special medical purpose formula foods is estimated at RMB 16.4 billion (approximately $2.27 billion) in 2024, holding the largest revenue share in the Asia-Pacific region, accounting for 9.15% of the global market [2]. - The Chinese market is expected to grow at a CAGR of 6.58%, reaching RMB 24 billion (approximately $3.33 billion) by 2030, indicating significant potential due to low current clinical usage rates compared to developed countries [2].